lifestyle.thepointnews.com

Author: IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

December 10, 2025
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

December 1, 2025
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

November 24, 2025